MILAN, Nov. 13, 2026 /PRNewswire/ — Bracco and Avicenna.AI today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of UPTUNITY™ | Aneurysm, the first offering within the new UPTUNITY™ portfolio and a result of Bracco’s collaboration with Avicenna.AI. Designed to support medical specialists in detecting and assessing brain aneurysms on cerebral arteries computed tomography angiography (CTA) images, UPTUNITY | Aneurysm integrates AI assistance into the radiologist’s reading workflow.
UPTUNITY reinforces Bracco’s Digital Health strategy by expanding the company’s capabilities into interpretive AI. The portfolio provides clinical decision support capabilities for specific needs in image interpretation. It complements Bracco’s existing AI offerings, including AiMIFY®, developed with Subtle Medical, which applies AI to amplify existing contrast enhancement in brain MRI for improved lesion visualization.1 With UPTUNITY, Bracco continues to invest in Digital Health technologies that extend its support for radiologists across the imaging continuum and advance innovation beyond contrast agents.